Also categorized in PubMed:
Treatment of chronic graft versus host disease with bortezomib.
x hide permanently

Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

ncbi.nlm.nih.gov

Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

J Natl Cancer Inst. 2017 Nov 01;109(11):

Authors: Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J